![]() Once established, it could allow for cost reduction and improve patient comfort.īetween May 2019 and January 2020, female patients who underwent breast surgery (breast-conserving surgery or mastectomy) and SNB for invasive breast cancer (cT1 to cT3, cN0, cM0) at the breast center of Charité-Universitätsmedizin Berlin were offered inclusion into the trial. Magtrace localization shortened the preoperative care pathway and did not affect surgical time or reimbursement. Reimbursement and pain levels remained unchanged, and the hospital length of stay was similar in the two groups (Magtrace: 5.1 ± 2.3 days vs Tc 99: 4.5 ± 3.2 days). The median time from probe usage to sentinel node extirpation was slightly but not significantly shorter in the Magtrace group (5 min interquartile range, 3–15 min vs 10 min IQR, 7–15 min p = 0.151). The mean time spent on the preoperative breast cancer care pathway was significantly shorter for the Magtrace group (5.4 ± 1.3 min) than for the Tc 99 group (82 ± 20 min) ( p < 0.0001). The secondary outcomes were patient pain levels and reimbursement. The primary outcomes were time spent on the care pathway and operating time from commissioning of the probe to removal of the sentinel node. Based on the surgeon’s choice, 29 patients were treated with Tc 99, and 30 patients received the iron-based tracer, Magtrace. This study compared 59 patients who underwent breast cancer surgery including sentinel lymph node biopsy. ![]() The timing of Tc 99 injection can complicate operating room schedules, which can cause increasing overall costs of care and patient discomfort. Drain placement at initial surgery may be considered in smokers or patients with diabetes.Sentinel lymph node biopsy after technetium-99 (Tc 99) localization is a mainstay of oncologic breast surgery. Management infrequently requires more than simple aspiration. Symptomatic axillary seroma occurs in 14 % patients undergoing breast-conserving surgery with SLNB and is not influenced by tumor, nodal mapping, or surgeon characteristics. The remainder resolved after axillary drain (13 of 98, 13 %) or additional surgery (4 of 98, 4 %). Among the 98 of 127 patients with seroma, most (81 of 98, 83 %) resolved with a mean of 1.3 aspirations. Multivariate analysis identified diabetes, smoking, and SSI as predictors of symptomatic axillary seroma with odds ratio of 1.97, 1.98, and 37.19 (all p < 0.017), respectively. Seroma rates did not vary according to surgeon, nodal mapping technique, or axillary closure technique (p = 0.8789). All statistical tests were two sided, with p 0.07). ![]() We correlated patient and tumor characteristics with symptomatic seroma using logistic regression models for univariate and multivariate predictors. Surgeons dissected sharply or with standard electrocautery. We performed a retrospective review of 667 women undergoing breast-conserving surgery and SLNB at our institution between July 2007 and January 2015. We sought to quantitate the risk of symptomatic seroma and characterize interventions. ![]() Few studies investigate predisposing factors for axillary seroma after sentinel lymph node biopsy (SLNB). Postoperative seroma is a nuisance for patients and surgeons. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |